Substituted piperidinyltetrahydroquinolines
The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.
1. A compound of the formula (I)
in which
R 1 represents C 1 -C 6 -alkyl or C 3 -C 5 -cycloalkyl,
where alkyl is substituted by 1 to 2 substituents independently of one another selected from the group consisting of hydroxy, C 1 -C 4 -alkoxy and haloalkoxy
and
R 2 represents hydrogen or C 1 -C 4 -alkyl,
or
R 1 and R 2 together with the nitrogen atom to which they are attached form a 4- to 7-membered N-heterocycle,
where the N-heterocycle may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of oxo, hydroxy, monofluoromethyl, difluoromethyl, trifluoromethyl, hydroxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, halogen and hydroxyalkyl,
or
where the N-heterocycle may have two substituents which, together with the carbon atom of the N-heterocycle to which they are jointly attached, form a 4- to 6-membered heterocycle,
where this heterocycle for its part may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of oxo, methyl and ethyl,
R 3 represents hydrogen, fluorine, methoxy or ethoxy
and
R 4 represents hydrogen, fluorine, methoxy or ethoxy,
and the salts thereof.
2. The compound of the formula (I) according to claim 1 in which
R 1 represents C 1 -C 6 -alkyl,
where alkyl is substituted by 1 to 2 substituents independently of one another selected from the group consisting of hydroxy and C 1 -C 4 -alkoxy
and
R 2 represents hydrogen or C 1 -C 4 -alkyl,
or
R 1 and R 2 together with the nitrogen atom to which they are attached form a 4- to 7-membered N-heterocycle,
where the N-heterocycle may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of oxo, hydroxy, monofluoromethyl, difluoromethyl, trifluoromethyl, hydroxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy and halogen,
or
where the N-heterocycle may have two substituents which, together with the carbon atom of the N-heterocycle to which they are jointly attached, form a 4- to 6-membered heterocycle,
where this heterocycle for its part may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of oxo, methyl and ethyl,
R 3 represents hydrogen, fluorine, methoxy or ethoxy,
and
R 4 represents hydrogen, fluorine, methoxy or ethoxy,
and the salts thereof.
3. The compound of the formula (I) according to claim 1 in which
R 1 represents C 2 -C 6 -alkyl,
where alkyl is substituted by a substituent selected from the group consisting of hydroxy, methoxy and ethoxy,
and
R 2 represents hydrogen,
or
R 1 and R 2 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, piperidine, azepane, piperazine, morpholine, thiomorpholine, 1-oxidothiomorpholine or 1,1-dioxidothiomorpholine,
where azetidine, pyrrolidine, piperidine, azepane, piperazine, morpholine, thiomorpholine, 1-oxidothiomorpholine and 1,1-dioxidothiomorpholine may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of hydroxy, hydroxycarbonyl, C 1 -C 3 -alkyl, trifluoromethyl, methoxy and methoxymethyl,
or
where azetidine, pyrrolidine, piperidine, azepane, piperazine and morpholine may have two substituents which, together with the carbon atom of the azetidine, pyrrolidine, piperidine, azepane, piperazine or morpholine to which they are jointly attached, form an azetidine, oxetane or 1,1-dioxidothietane,
where this azetidine, oxetane or 1,1-dioxidothietane for its part may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of methyl and ethyl,
R 3 represents hydrogen
and
R 4 represents hydrogen, fluorine or methoxy,
or
R 3 represents hydrogen, fluorine or methoxy
and
R 4 represents hydrogen,
and the salts thereof.
4. The compound of the formula (I) according to claim 1 in which
R 1 represents C 2 -C 4 -alkyl,
where alkyl is substituted by a substituent selected from the group consisting of hydroxy and methoxy,
and
R 2 represents hydrogen,
or
R 1 and R 2 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, morpholine or 1,1-dioxidothiomorpholine,
where azetidine, pyrrolidine, morpholine or 1,1-dioxidothiomorpholine may be substituted by 1 to 2 substituents selected independently from the group consisting of hydroxycarbonyl, methyl, trifluoromethyl, methoxy and methoxymethyl
or
R 1 and R 2 together with the nitrogen atom to which they are attached form an azetidine,
where the azetidine may have two substituents which, together with the carbon atom of the azetidine to which they are jointly attached, form an oxetane or 1,1-dioxidothietane,
R 3 represents hydrogen, fluorine or methoxy
and
R 4 represents hydrogen,
or
R 3 represents hydrogen,
and
R 4 represents hydrogen, fluorine or methoxy,
and the salts thereof.
5. The compound of the formula (I) according to claim 1 in which
R 1 represents C 2 -C 4 -alkyl,
where alkyl is substituted by a substituent selected from the group consisting of hydroxy and methoxy,
and
R 2 represents hydrogen,
or
R 1 and R 2 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, morpholine or 1,1-dioxidothiomorpholine,
where azetidine, pyrrolidine, morpholine or 1,1-dioxidothiomorpholine may be substituted by 1 to 2 substituents selected independently from the group consisting of hydroxycarbonyl, methyl, trifluoromethyl, methoxy and methoxymethyl
or
R 1 and R 2 together with the nitrogen atom to which they are attached form an azetidine,
where the azetidine may have two substituents which, together with the carbon atom of the azetidine to which they are jointly attached, form an oxetane or 1,1-dioxidothietane,
R 3 represents hydrogen or fluorine,
and
R 4 represents hydrogen, fluorine or methoxy,
and the salts thereof.
6. A method of making the compound of the formula (I) of claim 1 or one of the salts thereof,
wherein
[A] a compound of the formula (II)
is reacted with a compound of the formula (III)
in which R 3 and R 4 have the meanings given in claim 1 ,
in the presence of a reducing agent to give a compound of the formula (IV)
in which R 3 and R 4 have the meanings given in claim 1 ,
or
[B] compound of the formula (IV)
in which R 3 and R 4 have the meanings given in claim 1 ,
is reacted in the presence of an acid to give a compound of the formula (V)
in which R 3 and R 4 have the meanings given in claim 1 ,
or
[C] a compound of the formula (VI)
in which
X represents halogen, preferably fluorine, chlorine or bromine, or sulphonylmethane and
R 5 represents C 1 -C 4 -alkyl, preferably methyl or ethyl,
is reacted in the presence of a base with a compound of the formula (VII)
in which R 1 and R 2 have the meaning given in claim 1 ,
to give a compound of the formula (VIII)
in which R 1 and R 2 have the meaning given in claim 1 and R 5 is as defined above,
or
[D] a compound of the formula (IX)
in which
X represents halogen, preferably fluorine, chlorine or bromine, or sulphonylmethane,
is reacted with a compound of the formula (VII)
in which R 1 and R 2 have the meaning given in claim 1 ,
to give a compound of the formula (X)
in which R 1 and R 2 have the meaning given in claim 1 ,
or
[E] a compound of the formula (X)
in which R 1 and R 2 have the meaning given in claim 1 ,
is reacted with a compound of the formula (V)
in which R 3 and R 4 have the meanings given in claim 1 ,
in the presence of a dehydrating agent to give a compound of the formula (I)
or
[F] a compound of the formula (IX)
in which
X represents halogen, preferably fluorine, chlorine or bromine, or sulphonylmethane,
is reacted with compounds of the formula (V)
in which R 3 and R 4 have the meanings given in claim 1 ,
in the presence of a dehydrating agent to give a compound of the formula (XI)
in which
R 3 and R 4 have the meanings given in claim 1 and
X represents halogen, preferably fluorine, chlorine or bromine, or sulphonylmethane,
or
[G] a compound of the formula (XI)
in which
R 3 and R 4 have the meanings given in claim 1 and
X represents halogen, preferably fluorine, chlorine or bromine, or sulphonylmethane,
is reacted with a compound of the formula (VII)
in which R 1 and R 2 have the meaning given in claim 1 ,
to give the compound of the formula (I).
7. A compound of the formula (VIII) or (IX)
in which
R 1 and R 2 together with the nitrogen atom to which they are attached form a 1,1-dioxidothiomorpholine or azetidine,
where the azetidine has two substituents which, together with the carbon atom of the azetidine to which they are jointly attached, form an oxetane,
and
R 5 represents C 1 -C 4 -alkyl, preferably methyl or ethyl, and the salts thereof.
8. A method of antagonizing an adrenoreceptor in an individual that suffers from diabetic ulcers on the extremities comprising administering an effective amount of the compound of claim 1 .
9. A medicament comprising the compound of claim 1 in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
10. A medicament comprising the compound of claim 1 in combination with one or more further active compounds selected from the group consisting of lipid metabolism-modulating active compounds, antidiabetics, hypotensive agents, agent which lower the sympathetic tone, perfusion-enhancing and/or antithrombotic agents and also antioxidants, aldosterone and mineralocorticoide receptor antagonists, vasopressin receptor antagonists, organic nitrates and NO donors, IP receptor agonists, positive inotropic compounds, calcium sensitizers, ACE inhibitors, cGMP- and cAMP-modulating compounds, natriuretic peptides, NO-independent stimulators of guanylate cyclase, NO-independent activators of guanylate cyclase, inhibitors of human neutrophil elastase, compounds which inhibit the signal transduction cascade, compounds which modulate the energy metabolism of the heart, chemokine receptor antagonists, p38 kinase inhibitors, NPY agonists, orexin agonists, anorectics, PAF-AH inhibitors, antiphlogistics, analgesics, antidepressives and other psychopharmaceuticals.
11. A method of antagonizing an adrenoreceptor in an individual that suffers from at least one of primary and secondary forms of diabetic microangiopathies, diabetic wounds, diabetic ulcers on the extremities, diabetic foot ulcers, diabetic nephropathy, diabetic erectile dysfunction, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies comprising administering an effective amount of the medicament of claim 9 .
12. A method of antagonizing an adrenoreceptor in an individual that suffers from at least one of primary and secondary forms of diabetic microangiopathies, diabetic wounds, diabetic ulcers on the extremities, diabetic foot ulcers, diabetic retinopathy, diabetic nephropathy, diabetic erectile dysfunction, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiad vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies in humans and animals comprising administering an effective amount of the compound of claim 1 .
13. A method of antagonizing an adrenoreceptor in an individual that suffers from diabetic ulcers on the extremities comprising administering an effective amount of the medicament of claim 9 .
14. A method of antagonizing an adrenoreceptor in an individual that suffers from diabetic disorders or diabetic diseases comprising administering an effective amount of the compound of claim 1 .
15. A method of antagonizing an adrenoreceptor in an individual that suffers from diabetic disorders or diabetic diseases comprising administering an effective amount of the medicament of claim 9 .
16. A medicament comprising the compound of claim 1 in combination with one or more further active compounds selected from the group consisting of rivaroxaban, iloprost, and inhibitors of phosphodiesterases (PDE) 1, 2, 3, 4, and/or 5.
17. A method of antagonizing an adrenoreceptor in an individual that suffers from peripheral occlusive disease comprising administering an effective amount of the compound of claim 1 .
18. A method of antagonizing an adrenoreceptor in an individual that suffers from at least one of peripheral and cardiac vascular disorders, peripheral circulatory disturbances, or intermittent claudication comprising administering an effective amount of the compound of claim 1 .
19. A method of antagonizing an adrenoreceptor in an individual that suffers from peripheral occlusive disease comprising administering an effective amount of the medicament of claim 9 .
20. A method of antagonizing an adrenoreceptor in an individual that suffers from at least one of peripheral and cardiac vascular disorders, peripheral circulatory disturbances, or intermittent claudication comprising administering an effective amount of the medicament of claim 9 .